1. Efficacy of adalimumab in sarcoidosis
- Author
-
P. Van Biezen, J Bastiaans, G S Baarsma, Rwam Kuijpers, Lsj Kamphuis, W.K. Lam-Tse, Dik J. Kwekkeboom, P M van Hagen, W A Dik, Jam van Laar, Pla van Daele, and Herbert Hooijkaas
- Subjects
Medicine(all) ,medicine.medical_specialty ,Pathology ,Biochemistry, Genetics and Molecular Biology(all) ,business.industry ,Systemic sarcoidosis ,medicine.drug_class ,medicine.medical_treatment ,lcsh:R ,lcsh:Medicine ,General Medicine ,Monoclonal antibody ,medicine.disease ,Dermatology ,General Biochemistry, Genetics and Molecular Biology ,Cytokine ,Poster Presentation ,Adalimumab ,medicine ,In patient ,Sarcoidosis ,business ,Adverse effect ,medicine.drug - Abstract
Adverse effects and lack of specificity often hamper the use of conventional immunosuppressives in patients with systemic sarcoidosis. Adalimumab, a monoclonal antibody directed against the key cytokine involved in sarcoidosis, TNF-α, is used in patients with various immunological disorders [1]. Improved specificity, hence less adverse effects are the major advantages of this new class of drugs leading to an exponentially increasing role in their clinical use. However, few reports involving adalimumab in patients with sarcoidosis have been published so far and are restricted to case reports.
- Published
- 2010